Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$668.58 USD

668.58
1,298,850

+5.33 (0.80%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $667.86 -0.72 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (76 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

NEOGEN (NEOG) Adds to Prozap Insect Control Product Line-up

by Zacks Equity Research

NEOGEN's (NEOG) latest Prozap Protectus Pour-On Insecticide- IGR product relieves cattle from infestations.

Zacks Equity Research

Here's Why You Should Hold on to Cardiovascular Systems (CSII)

by Zacks Equity Research

Investors are optimistic about Cardiovascular Systems' (CSII) robust international growth and upcoming launches.

Zacks Equity Research

Here's Why You Should Retain SmileDirectClub (SDC) For Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub's (SDC) series of cutting-edge innovation, strategic distribution and insurance partnerships.

Zacks Equity Research

Bruker (BRKR) Unveils New Imaging Tools for Cancer Research

by Zacks Equity Research

Bruker's (BRKR) latest innovation for cancer research is likely to strengthen the company's opportunities in proteomics and spatial biology.

Zacks Equity Research

IDEXX (IDXX) CAG Sales Gain Traction, FX Headwind Persists

by Zacks Equity Research

IDEXX (IDXX) has been witnessing continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.

Zacks Equity Research

Here's Why You Should Retain Boston Scientific (BSX) For Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) robust organic sales and strategic buyouts.

Zacks Equity Research

Merit Medical's (MMSI) SCOUT Bx Delivery System Gets FDA Nod

by Zacks Equity Research

Merit Medical's (MMSI) receipt of FDA clearance for the SCOUT Bx system can streamline treatment for cancer patients.

Zacks Equity Research

Alcon (ALC) Stock Rallies 4.7% Since Posting Q4 Earnings Beat

by Zacks Equity Research

Alcon (ALC) stock rallies on robust growth across all Surgical and Vision Care sales categories.

Zacks Equity Research

Quidel Corporation (QDEL) Reports Solid Preliminary Q1 Revenues

by Zacks Equity Research

Quidel's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued robust sales of its SARS-related products.

Zacks Equity Research

Here's Why You Should Retain Thermo Fisher (TMO) For Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.

Zacks Equity Research

Here's Why You Should Hold on to Walgreens Boots (WBA) For Now

by Zacks Equity Research

Investors are optimistic about Walgreens (WBA) owing to the recent product launches.

Zacks Equity Research

The Zacks Analyst Blog Highlights Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group

by Zacks Equity Research

Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group are part of top Analyst Blog.

Zacks Equity Research

Charles River (CRL) Buys Explora BioLabs to Expand in CRO Space

by Zacks Equity Research

Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.

Zacks Equity Research

Alcon's (ALC) Surgical Arm Rebounds, New Launches Aid Growth

by Zacks Equity Research

In Vision Care, Alcon (ALC) continues to see strong demand for PRECISION1 and PRECISION1 for Astigmatism, which are the company's newest contact lenses for the mainstream market.

Zacks Equity Research

STERIS (STE) Up 8% Since Q3 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental growth and noteworthy acquisitions in the healthcare and pharmaceutical spaces.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock For Now

by Zacks Equity Research

Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.

Zacks Equity Research

Henry Schein (HSIC) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to favorable dental business trends and a strong solvency position.

Zacks Equity Research

Zacks.com featured highlights include The Kroger, NVIDIA, Jones Lang LaSalle, Paychex and McKesson

by Zacks Equity Research

The Kroger, NVIDIA, Jones Lang LaSalle, Paychex and McKesson are part of today's Screen of the Week article.

Zacks Equity Research

Edwards Lifesciences' (EW) Global Sales Robust Amid Cost Woes

by Zacks Equity Research

Edwards Lifesciences (EW) is registering robust HemoSphere sales in the United States.

Riya Anand headshot

Bet on These 4 Low-Beta, High-Dividend MedTech Stocks for 2022

by Riya Anand

Stocks like Becton, Dickinson and Company (BDX), Phibro Animal Health (PAHC), McKesson Corporation (MCK) and UnitedHealth Group Inc (UNH) are right picks with strong fundamentals.

Zacks Equity Research

Bruker's (BRKR) Buyout to Expand Mass Spectrometry Prospects

by Zacks Equity Research

Bruker's (BRKR) acquisition of IonSense will reach the DART ionization technology to a wider customer base.

Zacks Equity Research

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to the favorable dental business trends.

Zacks Equity Research

Here's Why You Should Hold on to Chemed (CHE) Stock For Now

by Zacks Equity Research

Investors are optimistic about robust performance by Chemed's (CHE) Roto-Rooter arm.

Zacks Equity Research

Here's Why You Should Retain Amedisys (AMED) Stock For Now

by Zacks Equity Research

Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.

Zacks Equity Research

Thermo Fisher (TMO) Debuts Raman Spectroscopic Analyzer

by Zacks Equity Research

Thermo Fisher's (TMO) Ramina Process Analyzer allows users to conduct precise in situ Raman measurements in a simple manner with high accuracy.